BioCentury on BioBusiness,
HGSI's gene database deadline
Monday, April 2, 2001
On June 30, Human Genome Sciences Inc.'s consortium of partners with
access to its database of full-length human mRNA sequences will dissolve, freeing HGSI to
repartner the database. With human sequence data increasingly available in the public
domain and in other commercial databases, it remains to be seen whether HGSI's database
will hold the same allure as it did in the mid-1990s, when the consortium members signed
The consortium includes Takeda Chemical Industries Ltd. (Osaka, Japan),
which last week announced that it had selected about 100 genes from the database for
development as small molecule or antibody therapeutic targets (see B5). The
remaining members include GlaxoSmithKline plc (GSK, London, U.K.), Schering-Plough Corp.
(SGP, Kenilworth, N.J
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]